| ²é¿´: 228 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
lw1966hhhÌú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
Ñо¿Ò»Ï·͸Éç¶ÔСÈÕ±¾Ò©ÎïÊг¡µÄ·ÖÎö¡¶Jp Pharm Companies Outlook¡·
|
||
|
The Japanese Pharmaceutical Companies Outlook: An analysis of key players and growth strategies evaluates the strengths and weaknesses of the top 10 Japanese pharmaceutical firms' strategic and financial positions, marketed portfolios and pipeline compounds. This report will enable you to assess the market dynamics within the Japanese pharma market and understand how companies are positioning themselves at a time of significant change in their domestic market. The Japanese pharmaceutical market is the second largest in the world, behind only the US, with estimated sales of $52bn in 2002. While it makes it an attractive target for Western companies' expansion plans, low market growth (1% in 2002) has made the operating environment increasingly difficult for domestic players. Coupled with ongoing regulatory reforms and drug price cuts, which are largely intended to reduce the government's healthcare bill, Japanese companies are being forced to adapt their operating strategies. http://rapidshare.de/files/28238 ... es_Outlook_2004.pdf |
» ²ÂÄãϲ»¶
ҩѧ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò© ºÓÄÏʦ·¶´óѧ¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ
ÒѾÓÐ0È˻ظ´
½Î÷
ÒѾÓÐ13È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ152È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ086ÉúÎïÓëÒ½Ò©
ÒѾÓÐ15È˻ظ´
½¥¶³Ö¢²¡Òò¼°¸ÉÔ¤·½°¸È«Ð½âÎö
ÒѾÓÐ2È˻ظ´
ÇóÖúÓÃ΢Æ×Êý¾Ý¿â²éѯÏà¹ØÎÄÏ×ÐÅÏ¢£¬·Ç³£¸Ðл
ÒѾÓÐ0È˻ظ´
NSCLCÄÔ×ªÒÆÖ×ÁöÄ£ÐÍ
ÒѾÓÐ0È˻ظ´
CHP-134Õâ¸öϸ°ûϵÄÄÀïÓУ¿
ÒѾÓÐ0È˻ظ´










»Ø¸´´ËÂ¥